Amgen seeks drug trial data before finalizing Onyx deal: sources

NEW YORK (Reuters) – Amgen Inc, the drugmaker in advanced discussions to buy Onyx Pharmaceuticals Inc, has asked Onyx for some of the data from an ongoing trial on the company’s new blood cancer drug, two people familiar with the matter said on Thursday.

Powered by WPeMatico

This entry was posted in World News. Bookmark the permalink.

Comments are closed.